Bank of America
CADL icon

Bank of America’s Candel Therapeutics CADL Stock Holding History

Bank of America’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Sell
47,402
-3,880
-8% -$21.1K ﹤0.01% 5282
2025
Q4 		$290K Buy
51,282
+3,639
+8% +$19.6K ﹤0.01% 5170
2025
Q3 		$243K Sell
47,643
-25,480
-35% -$147K ﹤0.01% 6185
2025
Q2 		$370K Sell
73,123
-106,128
-59% -$546K ﹤0.01% 5871
2025
Q1 		$1.01M Buy
179,251
+112,440
+168% +$919K ﹤0.01% 5205
2024
Q4 		$580K Buy
66,811
+44,952
+206% +$266K ﹤0.01% 5426
2024
Q3 		$151K Sell
21,859
-32,590
-60% -$202K ﹤0.01% 6152
2024
Q2 		$338K Buy
+54,449
New +$409K ﹤0.01% 5584
2024
Q1 		– Sell
-18
Closed -$26 – 7760
2023
Q4 		$26 Buy
+18
New +$17 ﹤0.01% 7606
2023
Q1 		– Sell
-22
Closed -$40 – 7836
2022
Q4 		$40 Sell
22
-184
-89% -$364 ﹤0.01% 7838
2022
Q3 		$0 Buy
206
+56
+37% +$190 ﹤0.01% 7849
2022
Q2 		$0 Sell
150
-1,312
-90% -$5.25K ﹤0.01% 8034
2022
Q1 		$7K Buy
1,462
+374
+34% +$1.86K ﹤0.01% 7816
2021
Q4 		$8K Buy
+1,088
New +$10.6K ﹤0.01% 7729

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's CADL Position: Q1 2026 in Review

Bank of America reduced its Candel Therapeutics (CADL) stake by 7.6% in Q1 2026, selling an estimated $21.1K and leaving 47,402 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #5282.

Bank of America first reported a position in CADL in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.01M in Q1 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Bank of America held 47,402 shares of Candel Therapeutics worth $232K as of Q1 2026.
  • Bank of America sold 3,880 Candel Therapeutics shares in Q1 2026, an estimated $21.1K.
  • Candel Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5282 holding.
  • Bank of America first reported a position in Candel Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Bank of America's Candel Therapeutics position peaked at $1.01M in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.